Calculate Your Salary Ranking
Home > MicuRx Pharmaceuticals Salary

MicuRx Pharmaceuticals Salary
  • 66
  • 90
  • 12

MicuRx Pharmaceuticals average salary is $85,176, median salary is $85,176 with a salary range from $85,176 to $85,176.
MicuRx Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. MicuRx Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 1 MicuRx Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Business Development Director 85,176-85,176 Hayward, CA, 94540 2015 MicuRx Pharmaceuticals Business Development Director Salaries (1)
MicuRx Pharmaceuticals Hayward, CA Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent MicuRx Pharmaceuticals Salaries (May 27, 2016)
Business Development Director MicuRx Pharmaceuticals $85,176 Hayward, CA, 94540 08/26/2015

MicuRx Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
MicuRx Pharmaceuticals Information
  • MicuRx Pharmaceuticals, Inc
  • Industry: BioTech/Drugs
  • City: Hayward, CA
  • MicuRx undertakes a highly efficient "de-risked" approach to expediently build a strong pipeline of pre-clinical and clinical products by focusing its innovative research on existing classes of under-explored but validated anti-infective structures. Based on advanced analysis of medical needs and identification of new scientific approaches to design superior pharmaceuticals, MicuRx team applies its unique expertise and creativity towards an expedient delivery of best-in-class agents with a blockbuster potential. With initial focus on antifungal and antibacterial chemotypes, this revolutionary strategy seeks to deliver IND candidates in a record short time.